All In Biotech

Drug Trial Radar · NCT06052267

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 2,769 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,769

Actual

Start

Aug 30, 2023

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to assess the efficacy of high dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). Secondary Objectives: To evaluate the efficacy of Fp/ABS low dose compared to ABS and the effect on systemic corticosteroid (SCS) exposure To evaluate the safety and tolerability of Fp/A BS The duration for each participant will be a minimum of 28 weeks including 2 weeks of screening, 2-4 weeks of run-in period and a double blind treatment period of minimum 24 weeks, however due to the event-driven nature of this study, the duration may range up to approximately 42 months depending on the timing when the participant was enrolled to the study, and when the study reaches its completion criteria

Conditions

  • Asthma

Interventions

  • TEV-56248Drug

    Fluticasone Propionate/Salbutamol Sulfate. Oral inhalation powder.

  • Albuterol sulfateDrug

    Oral inhalation powder

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Severe Clinical Asthma Exacerbation (CAE) with High Dose (HD) Fp/ABS eMDPITime frame: Up to 42 months

Locations

391 sites in 22 countries. Site status is shown where the registry gives one.

  • AllerVie Clnical Research

    Birmingham, Alabama

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • SEC Clinical Research

    Dothan, Alabama

  • One of a Kind Clinical Research Center LLC

    Paradise Valley, Arizona

  • Mayo Clinic

    Scottsdale, Arizona

  • Novak Clinical Research

    Tucson, Arizona

  • Kern Research, Inc

    Bakersfield, California

  • Clinical Research of Central California, LLC

    Fresno, California

  • Allergy and Asthma Specialists Medical Group

    Huntington Beach, California

  • Orso Health

    La Jolla, California

  • IMAX Clinical Trials

    La Palma, California

  • Long Beach Clinical Trials

    Long Beach, California

  • Ark Clinical Research, LLC

    Long Beach, California

  • Ricardo Antonio Tan Inc

    Los Angeles, California

  • One of a Kind Clinical Research Center LLC

    Napa, California

  • California Medical Research Associates Inc.

    Northridge, California

  • Riviera Allergy Medical Center

    Redondo Beach, California

  • Velocity Clinical Research, Banning

    San Bernardino, California

  • Institute of HealthCare Assessment, Inc

    San Diego, California

  • Allergy and Asthma Associates

    San Jose, California

  • Bensch Clinical Research LLC

    Stockton, California

  • Allianz Research Institute

    Westminster, California

  • Allianz Research Institute

    Aurora, Colorado

  • CRN Clinical Research Network LLC/Asthma and Allergy Associates P.C.

    Colorado Springs, Colorado

  • OptumCare Colorado Springs LLC

    Colorado Springs, Colorado

  • Velocity Clinical Research

    Englewood, Colorado

  • Emerson Clinical Research Institute

    Washington D.C., District of Columbia

  • Florida Center for Allergy and Asthma Research

    Aventura, Florida

  • Renaissance Research and Medical Group

    Cape Coral, Florida

  • Cenara Clinical Research

    Cutler Bay, Florida

  • D & H Doral Research Centers

    Doral, Florida

  • Finlay Medical Research Corp

    Greenacres City, Florida

  • Direct Helpers Research Center, Inc.

    Hialeah, Florida

  • New Life Research Institute, LLC

    Hialeah, Florida

  • Homestead Medical Research

    Homestead, Florida

  • Nemours Children Clinic

    Jacksonville, Florida

  • Clinical Site Partner, LLC DBA Flourish Research

    Leesburg, Florida

  • D & H Pompano Research Centers, Inc.

    Margate, Florida

  • EMDA Clinical Research

    Miami, Florida

  • Finlay Medical Research

    Miami, Florida

Showing 40 of 391 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.